The Market Reports

Synopsis
The global market for Liver Disease Diagnostics was estimated to be worth US$ 14210 million in 2024 and is forecast to a readjusted size of US$ 22740 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
The liver is an organ about the size of a football. It sits just under your rib cage on the right side of your abdomen. The liver is essential for digesting food and ridding your body of toxic substances. Liver disease can be inherited (genetic). Liver problems can also be caused by a variety of factors that damage the liver, such as viruses, alcohol use and obesity. Over time, conditions that damage the liver can lead to scarring (cirrhosis), which can lead to liver failure, a life-threatening condition. But early treatment may give the liver time to heal.
There are multiple causes of liver disease. While some are infective, some are genetic or autoimmune and some metabolic. This makes diagnosis difficult and often there are a battery of tests that need to be performed in order to correctly diagnose the underlying cause for the disease. Blood tests, biopsy and imaging tests are often used to check for liver disease.
Global key players of Liver Disease Diagnostics include Abbott, Roche and Thermo Fisher Scientific, etc. The top three players hold a share over 15%. North America is the largest market, has a share about 40%. In the market segment, imaging examinations (such as ultrasound, CT, MRI) dominate, accounting for about 60%, and are mainly used for screening and staging of diseases such as liver fibrosis and liver cancer. At the same time, in terms of downstream, hospitals and clinics are the largest downstream field, accounting for about 72% of the market share.
Future development trend
Early screening and early diagnosis technology breakthrough
Liquid biopsy (such as ctDNA, exosome detection) has great potential in early screening of liver cancer and can replace traditional invasive biopsy.
Multi-omics technology (genome, metabolomics) combined with AI models promotes personalized diagnosis and treatment.
Intelligent and digital integration
AI-assisted image analysis (such as liver cancer image segmentation, liver fibrosis staging) improves diagnostic efficiency.
Telemedicine and digital diagnosis and treatment platforms (such as liver disease full-process management APP) optimize patient follow-up processes.
Multidisciplinary collaboration and precision treatment
Combined medical and surgical treatment (such as the application of ERCP in complications of liver cirrhosis) and targeted drug development (such as HBV functional cure drugs) have become hot topics.
Regional market differentiation
North America is still the largest market (accounting for 40%), but Asia-Pacific (especially China) has the fastest growth rate, benefiting from policy support and the rise of local companies.
This report aims to provide a comprehensive presentation of the global market for Liver Disease Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liver Disease Diagnostics by region & country, by Purity, and by Application.
The Liver Disease Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liver Disease Diagnostics.
Market Segmentation
By Company
Abbott
Roche
Thermo Fisher Scientific
Randox Laboratories
Boston Scientific
LabCorp
Fujifilm Corporation
Siemens Healthineers
BD
Cook Medical
GE Healthcare
Philips Healthcare
Canon Medical Systems
Qiagen
Segment by Purity
Imaging Tests
Blood Tests
Biopsy
Segment by Application
Hospitals and Clinics
Diagnostic Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Liver Disease Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Purity, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Liver Disease Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Liver Disease Diagnostics in country level. It provides sigmate data by Purity, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index